A detailed history of D. E. Shaw & Co., Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 46,900 shares of NTLA stock, worth $565,145. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,900
Holding current value
$565,145
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $242,161 - $335,980
12,280 New
12,280 $252,000
Q4 2022

Feb 14, 2023

SELL
$33.21 - $62.69 $1.21 Million - $2.28 Million
-36,419 Reduced 70.62%
15,152 $528,000
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $20.2 Million - $26.9 Million
-374,779 Reduced 87.9%
51,571 $2.89 Million
Q2 2022

Aug 15, 2022

BUY
$38.49 - $76.21 $8 Million - $15.8 Million
207,941 Added 95.21%
426,350 $22.1 Million
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $12.6 Million - $25.7 Million
215,775 Added 8191.91%
218,409 $15.9 Million
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $745,422 - $1.02 Million
-7,398 Reduced 73.74%
2,634 $311,000
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $13.9 Million - $18.6 Million
-104,960 Reduced 91.28%
10,032 $1.35 Million
Q2 2021

Aug 16, 2021

SELL
$60.88 - $161.91 $17.6 Million - $46.7 Million
-288,728 Reduced 71.52%
114,992 $18.6 Million
Q1 2021

May 17, 2021

BUY
$46.59 - $83.68 $1.97 Million - $3.54 Million
42,349 Added 11.72%
403,720 $32.4 Million
Q4 2020

Feb 16, 2021

BUY
$18.83 - $63.53 $3.57 Million - $12 Million
189,402 Added 110.14%
361,371 $19.7 Million
Q3 2020

Nov 16, 2020

SELL
$17.47 - $24.93 $392,935 - $560,725
-22,492 Reduced 11.57%
171,969 $3.42 Million
Q2 2020

Aug 14, 2020

BUY
$11.14 - $22.87 $2.17 Million - $4.45 Million
194,461 New
194,461 $4.09 Million
Q1 2020

May 15, 2020

SELL
$9.44 - $15.58 $119,180 - $196,697
-12,625 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$10.43 - $17.67 $131,678 - $223,083
12,625 New
12,625 $185,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $916M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.